2,861 reports of this reaction
4.1% of all GEMCITABINE reports
#2 most reported adverse reaction
THROMBOCYTOPENIA is the #2 most commonly reported adverse reaction for GEMCITABINE, manufactured by Accord Healthcare Inc.. There are 2,861 FDA adverse event reports linking GEMCITABINE to THROMBOCYTOPENIA. This represents approximately 4.1% of all 70,539 adverse event reports for this drug.
Patients taking GEMCITABINE who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is moderately reported among GEMCITABINE users, representing a notable but not dominant share of adverse events.
In addition to thrombocytopenia, the following adverse reactions have been reported for GEMCITABINE:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 2,861 FDA reports for GEMCITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 4.1% of all adverse event reports for GEMCITABINE, making it one of the most commonly reported side effect.
If you experience thrombocytopenia while taking GEMCITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.